Combining two experimental cancer vaccines with Libtayo (cemiplimab) promotes strong anti-tumor immune responses and shows early signs of effectiveness in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer — according to interim data from a Phase 1/2 trial. Developed by Inovio Pharmaceuticals, the DNA-based vaccines, called INO-5401 and INO-9012, are meant to boost anti-tumor immune responses, which can lead to cancer cell death. Participants started the triple immunotherapy after surgery…
You must be logged in to read/download the full post.
The post Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer appeared first on BioNewsFeeds.